A study evaluating predictive role of ribavirin plasma levels for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination.

Trial Profile

A study evaluating predictive role of ribavirin plasma levels for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top